{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:55:36Z","timestamp":1790470536839,"version":"4.1.0"},"reference-count":75,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Novel antimicrobial agents, approved for clinical use in past years, represent potential treatment options for various infections. In this review, we summarize the most important medical and microbiological features of three recently approved fluoroquinolones, namely delafloxacin, finafloxacin, and zabofloxacin. Delafloxacin possesses an anionic chemical structure, and represents broad-spectrum activity, as it targets both bacterial DNA gyrase and topoisomerase IV enzymes of gram-positive and gram-negative bacteria with equal affinity. Its molecular surface is larger than that of other fluoroquinolones, and it has enhanced antibacterial efficacy in acidic environments. Delafloxacin has been approved to treat acute bacterial skin and skin-structure infections, as well as community-acquired bacterial pneumonia. Finafloxacin has a zwitterionic chemical structure, and targets both DNA gyrase and topoisomerase IV enzymes. This enables a broad antibacterial spectrum; however, finafloxacin has so far only been approved in ear-drops to treat bacterial otitis externa. Zabofloxacin is also a broad-spectrum fluoroquinolone agent, and was first approved in South Korea to treat acute bacterial exacerbation of chronic obstructive pulmonary disease. The introduction of these novel fluoroquinolones into daily practice extends the possible indications of antibiotics into different bacterial infections, and provides treatment options in difficult-to-treat infections. However, some reports of delafloxacin resistance have already appeared, thus underlining the importance of the prudent use of antibiotics.<\/jats:p>","DOI":"10.3390\/antibiotics10121506","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T21:52:32Z","timestamp":1639086752000},"page":"1506","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-7055","authenticated-orcid":false,"given":"B\u00e9la","family":"Kocsis","sequence":"first","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Guly\u00e1s","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13756-019-0590-7","article-title":"Economic burden of antibiotic resistance in ESKAPE organisms: A systematic review","volume":"8","author":"Zhen","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(16)30257-2","article-title":"European survey of carbapenemase-producing enterobacteriaceae (EuSCAPE) working group. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): A prospective, multinational study","volume":"17","author":"Grundmann","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41564-019-0492-8","article-title":"Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread","volume":"4","author":"David","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: No ESKAPE! An update from the infectious diseases society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"212527","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived?","volume":"64","author":"Livermore","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21\u201322","author":"Oliver","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa Mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","article-title":"Antibiotics in the clinical pipeline in October 2019","volume":"73","author":"Butler","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_11","first-page":"704","article-title":"Plazomicin: A new aminoglycoside","volume":"70","author":"Saravolatz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: Discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/IDR.S150447","article-title":"Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae","volume":"11","author":"Petty","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/00325481.2019.1680052","article-title":"Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents","volume":"132","author":"Bader","year":"2020","journal-title":"Postgrad. Med."},{"key":"ref_16","unstructured":"US Food and Drug Administration (2018, December 08). BAXDELA (Delafloxacin) Prescribing Information and Medication Guide, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000,208611s000lbl.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rusu, A., Lungu, I.A., Moldovan, O.L., Tanase, C., and Hancu, G. (2021). Structural characterization of the millennial antibacterial (fluoro) quinolones-shaping the fifth generation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081289"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105987","DOI":"10.1016\/j.ijantimicag.2020.105987","article-title":"Plasmids and genes contributing to high-level quinolone resistance in Escherichia coli","volume":"56","author":"Sater","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2016.09.001","article-title":"Plasmid-mediated quinolone resistance: Two decades on","volume":"29","author":"Machuca","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/mdr.2018.0245","article-title":"Ciprofloxacin promoted qnrD expression and phylogenetic analysis of qnrD harboring plasmids","volume":"25","author":"Kocsis","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"ref_23","first-page":"169","article-title":"Plasmid copy number and qnr gene expression in selection of fluoroquinolone-resistant Escherichia coli","volume":"66","author":"Kocsis","year":"2019","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/cid\/ciy1079","article-title":"Profile of a novel anionic fluoroquinolone-delafloxacin","volume":"68","author":"Tulkens","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","unstructured":"European Medicines Agency (EMA) (2018, December 08). Quinolone- and Fluoroquinolone-Containing Medicinal Products: Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.48.7.2771-2777.2004","article-title":"In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms","volume":"48","author":"Almer","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/cid\/ciy600","article-title":"Delafloxacin: A new anti\u2013methicillin-resistant Staphylococcus aureus Fluoroquinolone","volume":"68","author":"Saravolatz","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: A novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","volume":"38","author":"Hoover","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcph.817","article-title":"Clinical pharmacology of delafloxacin in patients with hepatic impairment","volume":"57","author":"Hoover","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_33","unstructured":"Hoover, R., Lawrence, L., Smith, C., and Longcor, J. (2013, January 10\u201313). Pharmacokinetics (PK) of delafloxacin (DLX) in patients with varying degrees of renal impairment. Proceedings of the Fifty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA. Poster A-017e."},{"key":"ref_34","unstructured":"(2021, September 10). Center for Drug Evaluation and Research: Delafloxacin NDA Briefing, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208610Orig1s000,208611Orig1s000Approv.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijid.2014.10.009","article-title":"A randomized Phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections","volume":"30","author":"Mehra","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40261-020-00953-z","article-title":"Community-acquired bacterial pneumonia-changing epidemiology, resistance patterns, and newer antibiotics: Spotlight on delafloxacin","volume":"40","author":"Sharma","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_38","first-page":"e02803-17","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance","volume":"60","author":"Soge","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/dkh304","article-title":"The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae","volume":"54","author":"Hammerschlag","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.47.12.3973-3975.2003","article-title":"Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114980","DOI":"10.1016\/j.diagmicrobio.2019.114980","article-title":"Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?","volume":"96","author":"Boyanova","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_43","unstructured":"Melinta Therapeutics (2020, March 16). Baxdela (Delafloxacin) Tablets, for Oral Use; Baxdela (Delafloxacin) for Injection, for Intravenous Use: US Prescribing Information. Available online: https:\/\/baxdela.com\/docs\/baxdela-prescribing-information.pdf."},{"key":"ref_44","unstructured":"European Medicines Agency (2020, March 16). Quofenix (Delafloxacin): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: A review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin\u2014A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin. Respir. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: Resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of delafloxacin-resistant Staphylococcus aureus in Brooklyn, New York","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1128\/AAC.00832-10","article-title":"Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e02317-17","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","unstructured":"US Food and Drug Administration (2021, August 20). XTORO Prescribing Information and Medication Guide 2014, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206307s000lbl.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2011.03.002","article-title":"Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila","volume":"38","author":"Lemaire","year":"2011","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1093\/jac\/dkq375","article-title":"Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance","volume":"65","author":"Emrich","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1128\/AAC.00886-10","article-title":"Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine","volume":"55","author":"Dalhoff","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e02325-17","DOI":"10.1128\/AAC.02325-17","article-title":"Early clinical assessment of the antimicrobial activity of finafloxacin compared to ciprofloxacin in subsets of microbiologically characterized isolates","volume":"62","author":"Vente","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e02328-17","DOI":"10.1128\/AAC.02328-17","article-title":"Population pharmacokinetics of finafloxacin in healthy volunteers and patients with complicated urinary tract infections","volume":"62","author":"Taubert","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/13543784.2015.1052401","article-title":"Finafloxacin for the treatment of urinary tract infections","volume":"24","author":"Bartoletti","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e01061-21","DOI":"10.1128\/AAC.01061-21","article-title":"Intracellular activity of antibiotics against Coxiella burnetii in a model of activated human THP-1 cells","volume":"65","author":"Peyrusson","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1254.e1","DOI":"10.1016\/j.cmi.2019.07.028","article-title":"Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes","volume":"26","author":"Chalhoub","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e01470-19","DOI":"10.1128\/AAC.01470-19","article-title":"Demonstration of the broad spectrum in vitro activity of finafloxacin against pathogens of biodefence interest","volume":"63","author":"Barnes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3389\/fmicb.2019.00904","article-title":"The fluoroquinolone finafloxacin protects BALB\/c Mice against an intranasal infection with francisella tularensis strain SchuS4","volume":"10","author":"Barnes","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_63","first-page":"1258","article-title":"Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance","volume":"72","author":"Randall","year":"2017","journal-title":"J. Antimicrob Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00082-17","DOI":"10.1128\/AAC.00082-17","article-title":"Demonstrating the protective efficacy of the novel fluoroquinolone finafloxacin against an inhalational exposure to burkholderia pseudomallei","volume":"61","author":"Barnes","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e02294-20","DOI":"10.1128\/AAC.02294-20","article-title":"finafloxacin is an effective treatment for inhalational tularemia and plague in mouse models of infection","volume":"65","author":"Barnes","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1128\/AAC.01407-05","article-title":"In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone","volume":"50","author":"Park","year":"2006","journal-title":"Antimicrob. Agent Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1358\/dot.2016.52.9.2530595","article-title":"Zabofloxacin for chronic bronchitis","volume":"52","author":"Kocsis","year":"2016","journal-title":"Drugs Today"},{"key":"ref_68","unstructured":"(2021, August 20). Dong Wha Obtains Approval for Zabolante from MFDS (Press Release 20 March 2015). Available online: https:\/\/www.dong-wha.co.kr\/english\/customer\/dnews\/content.asp?t_idx=856."},{"key":"ref_69","unstructured":"(2021, August 20). Dong Wha Pharm\u2019s Quinolone Antibacterial Agent, \u201cZabolante,\u201dWins at the 19th KNDA (Press Release 28 February 2018). Available online: https:\/\/www.dong-wha.co.kr\/english\/customer\/dnews\/content.asp?t_idx=1139."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/07853890.2014.935470","article-title":"Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones","volume":"46","year":"2014","journal-title":"Ann. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jac\/dkl304","article-title":"In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent","volume":"58","author":"Kwon","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Park, H.-S., Oh, S.-H., Kim, H.-S., Choi, D.-R., and Kwak, J.-H. (2016). Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniae. Molecules, 21.","DOI":"10.3390\/molecules21111562"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diagmicrobio.2008.05.010","article-title":"Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains","volume":"62","author":"Jones","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1185\/03007995.2013.825591","article-title":"Comparison of pharmacokinetics between new quinolone antibiotics: The zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet","volume":"29","author":"Han","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/COPD.S90948","article-title":"Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: A multicenter, double-blind, double-dummy, randomized, controlled, phase III, non-inferiority trial","volume":"10","author":"Rhee","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/12\/1506\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:43:07Z","timestamp":1760168587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/12\/1506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["antibiotics10121506"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10121506","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]}}}